Regulus Therapeutics Inc RGLS

NAS: RGLS | ISIN: US75915K2006   30/04/2025
7,980 USD (+136,80%)
(+136,80%)   30/04/2025

30 april 2025 · Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG · Persbericht

2 april 2025 · Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit · Persbericht

27 maart 2025 · Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) · Persbericht

13 maart 2025 · Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates · Persbericht

4 maart 2025 · Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare Conference · Persbericht

28 augustus 2024 · Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences · Persbericht

8 augustus 2024 · Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates · Persbericht

6 augustus 2024 · Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference · Persbericht

9 juli 2024 · Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences · Persbericht

24 juni 2024 · Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) · Persbericht

4 juni 2024 · Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes · Persbericht

16 mei 2024 · Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer · Persbericht

9 mei 2024 · Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates · Persbericht

6 mei 2024 · Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) · Persbericht

30 april 2024 · Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series · Persbericht

21 maart 2024 · Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates · Persbericht

12 maart 2024 · Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity · Persbericht

12 maart 2024 · Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) · Persbericht

2 januari 2024 · Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) · Persbericht

9 november 2023 · Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates · Persbericht

Mijn selecties